ARTEMIDE-Biliary02: A phase 3, randomized, global study of rilvegostomig or durvalumab with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC).

Imfinzi (durvalumab) - AstraZeneca

gemcitabine - Generic mfg.

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

cisplatin - Generic mfg.

https://www.asco.org/abstracts-presentations/266882

Lipika Goyal; Fang Zhao; Changhoon Yoo; Angela Lamarca; Rachna Shroff; Makoto Ueno; Arndt Vogel; Jian Zhou; Xin Chen; Hamzeh Kayhanian; Karolina Laskowska-Macios

Apr 21, 2026